BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, Smorenburg CH, Nortier JW, Gelderblom H, Guchelaar HJ. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol 2013;71:593-601. [PMID: 23228987 DOI: 10.1007/s00280-012-2034-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Binkhorst L, Mathijssen RH, Jager A, van Gelder T. Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping. Cancer Treatment Reviews 2015;41:289-99. [DOI: 10.1016/j.ctrv.2015.01.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
2 De Kesel PMM, Lambert WE, Stove CP. Alternative Sampling Strategies for Cytochrome P450 Phenotyping. Clin Pharmacokinet 2016;55:169-84. [DOI: 10.1007/s40262-015-0306-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
3 Safgren SL, Suman VJ, Kosel ML, Gilbert JA, Buhrow SA, Black JL, Northfelt DW, Modak AS, Rosen D, Ingle JN, Ames MM, Reid JM, Goetz MP. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenet Genomics 2015;25:157-63. [PMID: 25714002 DOI: 10.1097/FPC.0000000000000121] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Hwang GS, Bhat R, Crutchley RD, Trivedi MV. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J 2018;18:201-8. [DOI: 10.1038/tpj.2017.36] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
5 Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ. Further characterization of a 13 C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy. J Breath Res 2015;9:026003. [DOI: 10.1088/1752-7155/9/2/026003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79:222-240. [PMID: 24913012 DOI: 10.1111/bcp.12441] [Cited by in Crossref: 130] [Cited by in F6Publishing: 103] [Article Influence: 18.6] [Reference Citation Analysis]
7 Opdam FL, Modak AS, Mooijaart SP, Louwerens M, de Waal MW, Gelderblom H, Guchelaar HJ. CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study. Drugs Aging 2015;32:1019-27. [PMID: 26597400 DOI: 10.1007/s40266-015-0319-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Wang X, Zhang H, Wang J, Yu G, Cui L, Guo M. EpiHNet: Detecting epistasis by heterogeneous molecule network. Methods 2021:S1046-2023(21)00221-8. [PMID: 34555529 DOI: 10.1016/j.ymeth.2021.09.007] [Reference Citation Analysis]
9 Modak AS. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. J Breath Res 2017;12:017101. [PMID: 28920579 DOI: 10.1088/1752-7163/aa8d2e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 von Grafenstein S, Fuchs JE, Huber MM, Bassi A, Lacetera A, Ruzsanyi V, Troppmair J, Amann A, Liedl KR. Precursors for cytochrome P450 profiling breath tests from an in silico screening approach. J Breath Res 2014;8:046001. [PMID: 25233885 DOI: 10.1088/1752-7155/8/4/046001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Gusella M, Pasini F, Corso B, Bertolaso L, De Rosa G, Falci C, Modena Y, Barile C, Da Corte Z D, Fraccon A, Toso S, Cretella E, Brunello A, Modonesi C, Segati R, Oliani C, Minicuci N, Padrini R; Italian TAM Group. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable? Pharmacol Res Perspect 2020;8:e00646. [PMID: 32813313 DOI: 10.1002/prp2.646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jager NG, Linn SC, Schellens JH, Beijnen JH. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clin Breast Cancer 2015;15:241-4. [PMID: 25997856 DOI: 10.1016/j.clbc.2015.04.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
13 de Krou S, Rosing H, Nuijen B, Schellens JHM, Beijnen JH. Fast and Adequate Liquid Chromatography–Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2017;39:132-7. [DOI: 10.1097/ftd.0000000000000372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
14 Keller J, Hammer HF, Afolabi PR, Benninga M, Borrelli O, Dominguez-Munoz E, Dumitrascu D, Goetze O, Haas SL, Hauser B, Pohl D, Salvatore S, Sonyi M, Thapar N, Verbeke K, Fox MR; European 13C-breath test group. European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC. United European Gastroenterol J 2021;9:598-625. [PMID: 34128346 DOI: 10.1002/ueg2.12099] [Reference Citation Analysis]
15 Sanchez-spitman A, Swen J, Dezentje V, Moes D, Gelderblom H, Guchelaar H. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Review of Clinical Pharmacology 2019;12:523-36. [DOI: 10.1080/17512433.2019.1610390] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
16 Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ. Breath tests to phenotype drug disposition in oncology. Clin Pharmacokinet 2013;52:919-26. [PMID: 23868281 DOI: 10.1007/s40262-013-0099-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Modak AS. Regulatory issues on breath tests and updates of recent advances on [ 13 C]-breath tests. J Breath Res 2013;7:037103. [DOI: 10.1088/1752-7155/7/3/037103] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
18 Shah RR, Gaedigk A, Llerena A, Eichelbaum M, Stingl J, Smith RL. CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics 2016;17:259-75. [DOI: 10.2217/pgs.15.172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
19 ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, Huitema AD. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. Br J Clin Pharmacol 2014;78:572-86. [PMID: 24697814 DOI: 10.1111/bcp.12388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
20 de Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, König-quartel JMC, Hessing T, Guchelaar HJ, van Erp NP. Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother Pharmacol 2014;73:87-96. [DOI: 10.1007/s00280-013-2322-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]